SEED-Selection enables high-efficiency enrichment of primary T cells edited at multiple loci
Engineering T cell specificity and function at multiple loci can generate more effective cellular therapies, but current manufacturing methods produce heterogenous mixtures of partially engineered cells. Here we develop a one-step process to enrich unlabeled cells containing knock-ins at multiple target loci using a family of repair templates named synthetic exon expression disruptors (SEEDs). SEEDs associate transgene integration with the disruption of a paired target endogenous surface protein while preserving target expression in nonmodified and partially edited cells to enable their removal (SEED-Selection). We design SEEDs to modify three critical loci encoding T cell specificity, coreceptor expression and major histocompatibility complex expression. The results demonstrate up to 98% purity after selection for individual modifications and up to 90% purity for six simultaneous edits (three knock-ins and three knockouts). This method is compatible with existing clinical manufacturing workflows and can be readily adapted to other loci to facilitate production of complex gene-edited cell therapies.
Authors
- Chun Jimmie Ye (ORCID: https://orcid.org/0000-0001-6560-3783)
- Chang Liu
- Joseph J. Muldoon (ORCID: https://orcid.org/0000-0003-3784-3565)
- Charlotte H. Wang (ORCID: https://orcid.org/0000-0001-7588-2077)
- Vivasvan S. Vykunta (ORCID: https://orcid.org/0000-0002-5409-8635)
- Thomas Mazumder (ORCID: https://orcid.org/0000-0003-2427-2652)
- Justin Eyquem (ORCID: https://orcid.org/0000-0001-8262-1190)
- Jae Hyun J. Lee
- Brian R. Shy (ORCID: https://orcid.org/0000-0001-9569-3708)
- Vincent Allain (ORCID: https://orcid.org/0000-0002-1068-7892)
- Daniel B. Goodman (ORCID: https://orcid.org/0000-0003-3759-6883)
- Alexander Marson (ORCID: https://orcid.org/0000-0002-2734-5776)
- William A. Nyberg (ORCID: https://orcid.org/0000-0002-9982-1305)
- Allison Rothrock
- Clara Kochendoerfer
- Lian Li (ORCID: https://orcid.org/0000-0003-4700-1134)
- Yang Sun (ORCID: https://orcid.org/0000-0002-9344-8060)
- Christopher Chang (ORCID: https://orcid.org/0000-0003-3124-8773)
Institutions
- Gladstone Institutes (US)
- Inserm (FR)
- University of California, San Francisco (US)
- Université Paris Cité (FR)
- Innovative Genomics Institute (US)
- Parker Institute for Cancer Immunotherapy (US)
- Palo Alto Institute (US)
- Hôpital Saint-Louis (FR)
- UCSF Helen Diller Family Comprehensive Cancer Center (US)
- Arc Research Institute
- University of California, Berkeley (US)
Publication Details
- Journal
- Nature Biotechnology
- Published
- 2025-02-05
- DOI
- https://doi.org/10.1038/s41587-024-02531-6
- Citations
- 12
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 12.54
Funders
- Cancer Research Institute
- National Institute of General Medical Sciences